Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

TRICHOSPORON-BEIGELII, AN EMERGING PATHOGEN RESISTANT TO AMPHOTERICIN-B JOURNAL OF CLINICAL MICROBIOLOGY Walsh, T. J., Melcher, G. P., Rinaldi, M. G., LECCIONES, J., MCGOUGH, D. A., Kelly, P., Lee, J., Callender, D., Rubin, M., Pizzo, P. A. 1990; 28 (7): 1616-1622

Abstract

Trichosporon beigelii caused fatal disseminated infections that were resistant to amphotericin B in two granulocytopenic patients. In vitro susceptibility studies demonstrated that both index strains of T. beigelii were inhibited but not killed by amphotericin B at achievable concentrations in serum. The minimum lethal concentration for both isolates was greater than or equal to 18 micrograms/ml. Five of seven other isolates were found to have a similar pattern of amphotericin B resistance. The fact that the minimum lethal concentration of T. beigelii was many times greater than its MIC was consistent with a resistance pattern of tolerance. We concluded that T. beigelii may be resistant in vitro to amphotericin B and that this in vitro resistance was correlated with refractory, disseminated trichosporonosis in granulocytopenic patients. T. beigelii should be included in the expanding list of amphotericin B-resistant fungi.

View details for Web of Science ID A1990DK19400025

View details for PubMedID 2380383